2026-09-28T02:04:00Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/116202026-05-15T06:32:10Zcom_10259_11209com_10259_5086com_10259_2604col_10259_11210

Pérez Gómez, Noelia Martínez-Zamora, María Ángeles Carmona, Francisco Novalbos, Jesús Abad-Santos, Francisco Koller, Dora Saiz Rodríguez, Miriam 2026-05-14T07:56:16Z 2026-05-14T07:56:16Z 2026-03 0724-8741 https://hdl.handle.net/10259/11620 10.1007/s11095-026-04049-9 1573-904X Endometriosis is a chronic inflammatory disease characterized by the presence of endometrial-like tissue outside the uterine cavity. It affects approximately 10–15% of women of reproductive age globally and is characterized by heterogeneous symptoms with chronic pelvic pain, dysmenorrhea, and infertility being the most common. Although pharmacological treatments are available to manage its symptoms, many women either do not respond to these therapies or experience adverse drug reactions (ADRs) that outweigh the original symptoms of endometriosis. Current research highlights a critical gap in pharmacogenetic biomarkers for endometriosis treatment, limiting the potential for personalized therapeutic strategies. Integrative multi-omics approaches combining genetic, inflammatory, and hormonal profiles may enhance patient stratification and optimize individualized care. Open access funding provided by FEDER European Funds and the Junta de Castilla y León under the Research and Innovation Strategy for Smart Specialization (RIS3) of Castilla y León 2021-2027. The authors acknowledge support from “Fundació de la Marató” (project PI049956). D.K.is supported by a ‘Ramón y Cajal’ fellowship from the Spanish Ministry of Science and Innovation (RYC2024-050099-I). The contract of N.P.G. was funded by the predoctoral research personnel hiring program, co-funded by the European Social Fund Plus (ESF +) of the Ministry of Education of the Regional Government of Castilla y León (BU-103–25). Open access funding provided by FEDER European Funds and the Junta De Castilla y León under the Research and Innovation Strategy for Smart Specialization (RIS3) of Castilla y León 2021-2027 Application/pdf eng Springer Pharmaceutical Research. 2026, V. 43, n. 3, p. 605-618 https://doi.org/10.1007/s11095-026-04049-9 Atribución 4.0 Internacional http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Drug response Endometriosis Pharmacogenetics Precision medicine Endometriosis An Overview of Endometriosis and Potential Pharmacogenetic Targets info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Pharmaceutical Research 43 3 605 618https://ror.org/051jb1k20Consorcio de Bibliotecas Universitarias de Castilla y León (BUCLE)hybrid-oa12349,58 EURSpringer Nature2025-01-012027-12-3110.1007/s11095-026-04049-9